IMF Presents Top Ten Oral and Poster Abstracts at the 2024 ASH Annual Meeting

 

Oral and poster abstracts co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru, IMF Chief Medical Officer Dr. Joseph Mikhael, and members of the IMF Scientific Advisory Board (SAB). 

 

STUDIO CITY, CA, December 13, 2024 —The International Myeloma Foundation proudly presented its top ten ASH oral and poster abstracts, including those from IMF President & CEO and 29-year myeloma patient Yelak Biru, IMF Chief Medical Officer Dr. Joseph Mikhael, and members of the IMF Scientific Advisory Board (SAB). 

The oral and poster abstracts were presented during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA which took place from December 7-10, 2024.  

The oral and poster presentations investigated the following:  

    1. “An updated interim analysis of the DREAMM-9 Trial—an ongoing randomized Phase 1 dose optimization study evaluating belantamab mafodotin (belamaf) plus bortezomib, lenalidomide, and dexamethasone (VRd) in autologous stem cell transplant (ASCT)-ineligible newly diagnosed multiple myeloma (TI NDMM).” (Abstract #497: Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis, co-authored by IMF SAB Member Saad Z. Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, NY) 

 

    2. “In patients with newly diagnosed multiple myeloma (NDMM) who are not candidates for transplant, VMP (bortezomib, melphalan, prednisone) and Rd (lenalidomide, dexamethasone) have been standard treatments. The Spanish Myeloma Group combined 9 cycles of VMP and 9 cycles of Rd, yielding good results for ‘fit’ patients aged 65-80.” (Abstract #678 GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation, co-authored by IMF SAB Member Maria-Victoria Mateos, MD, PhD, of the University of Salamanca in Salamanca, Spain) 

 

    3. “A retrospective analysis utilizing the International Myeloma Foundation (IMF) immunotherapy database with the objective of understanding the outcomes of older adults (age ≥ 70) including frail patients treated in the real-world with teclistamab.” (Abstract# 704 Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis, co-authored by IMF SAB Member Thomas Martin, MD, of University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center in San Francisco, CA) 

 

    4. “DREAMM-7 (NCT04246047) is a global, 1:1 randomized, open-label, phase 3, head-to-head trial comparing the efficacy and safety of 2 triplets—belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd)—in patients with progression of MM after ≥1 prior line of therapy. The primary endpoint was independent review committee–assessed PFS.” (Abstract # 772 Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial, co-authored by IMF SAB Member Vania Hungria, MD, PhD, of Clinica São Germano in São Paulo, Brazil) 

 

    5.  “Based on the encouraging activity and tolerability observed with DARA monotherapy in patients with intermediate- or high-risk SMM in the phase 2 CENTAURUS study, the phase 3 AQUILA study sought to determine if DARA could delay progression to MM versus active monitoring. Here we report the primary analysis from the AQUILA study.” (Abstract # 773 Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study, co-authored by IMF Chairperson of the Board and SAB Member S. Vincent Rajkumar, MD of Mayo Clinic in Rochester, MN) 

 

    6.  “A prospective study conducted from March to June 2024 using 30-minute web-based quantitative surveys fielded in 2269 participants (1301 RRMM patients and 968 HCPs) across 7 countries (US, UK, France, Germany, Italy, Spain, Japan). The survey collected data on pre-defined patient subgroups (line of treatment, ages <45, 46-65, 65+]) and in HCP subgroups (care settings: academic, community [non-Center of Excellence [COE]). Data were analyzed using descriptive statistics and chi-square tests.” (Abstract # 3658 Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study, co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru) 

 

    7. “Clinical trial registries (WHO, ClinicalTrials.gov, and EUCTR) were searched for clinical trials in MM that were registered between 2011 and 2021. Data were analyzed to determine the countries in which MM clinical trials recruited patients and how many trials took place. A systematic literature review was conducted in line with PRISMA recommendations to identify barriers and facilitators to enrollment in MM clinical trials. Three electronic databases were searched since their inception: MEDLINE, Embase, and APA PsycInfo.” (Abstract #3788 Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma, co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru) 

 

    8. “Retrospectively established a registry of neurological toxicities (NTs) via the Immune Therapy Working Committee of the International Myeloma Working Group (IMWG). Gathered data pertaining to demographics, MM characteristics, MM response, NT signs/symptoms, diagnostic workup, and treatment.” (Abstract # 4758 Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry, co-authored by IMF SAB Member Thomas Martin, MD, of University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center in San Francisco, CA) 

 

    9. “A Quality Improvement (QI) initiative which included 78 provider surveys, with pre- and post-surveys from 64 and 31 providers, respectively, participating in team-based audit-feedback (AF) sessions, and 90-day follow-up (FL/U) surveys. The surveys evaluated practice patterns, challenges, and barriers to equitable care. Care teams from each clinic, along with a regional MM expert and a nationally renowned MM physician, participated in AF sessions to (a) assess system-specific practice gaps identified via the surveys, (b) prioritize areas for improvement, and (c) develop action plans to address root causes.” (Abstract #5034 Advancing Patient-Centered Care to Overcome Health Disparities in Multiple Myeloma: Key Findings from a Quality Improvement Initiative, co-authored by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP of TGen, City of Hope in Phoenix, AZ) 

 

    10. “An international multicenter retrospective study of patients with relapsed/refractory multiple myeloma (RRMM) treated with tec on-label at 9 academic centers from 5 countries (United States, United Kingdom, Greece, Spain, and Canada) through the International Myeloma Working Group (IMWG) Immunotherapy Committee. Patients with RRMM treated with commercial tec at the respective institutions between May 24, 2022, to January 4, 2024, were included.”(Abstract # 5166 Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee, co-authored by IMF SAB Members, Saad Z. Usmani, MD, and Thomas Martin, MD) 
 

To learn more about the 2024 ASH Abstracts, visit hematology.org. 

For more in-depth insights on the latest myeloma research from the 2024 ASH Annual Meeting, the IMF invites you to register and join the IMWG Conference Series: Making Sense of Treatment ASH 2024 on Wednesday, December 18, 2024; and the Latest Myeloma Updates from ASH 2024: Easy-to-Understand Insights For Patients and Care Partners on Wednesday, January 8, 2025.

Additionally, IMF Chief Medical Officer Dr. Mikhael will feature an in-depth article on ASH 2024 in the Winter Edition of Myeloma Today. 

Join the ASH 2024 conversation by following the IMF on social media:   

X/Twitter: @IMFmyeloma   

Instagram: @imfmyeloma  


Facebook: @myeloma  


LinkedIn: International Myeloma Foundation